Procomvax Uniunea Europeană - slovenă - EMA (European Medicines Agency)

procomvax

sanofi pasteur msd, snc - polyribosylribitol fosfat iz haemophilus influenzae tipa b, kot prp-ompc, zunanja membrana, beljakovine kompleks neisseria meningitidis (zunanje membrane protein complex v b11 sev neisseria meningitidis podskupini b), adsorbira hepatitis b surface antigen, proizvedene v rekombinantne kvasovke celic (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - cepiva - procomvax je indicirano za cepljenje proti invazivni bolezni, ki povzroča haemophilus influenzae tipa b in proti okužbi, zaradi vseh znanih podtipov virusa hepatitisa b pri dojenčkih 6 tednov do 15 mesecev starosti.

Quintanrix Uniunea Europeană - slovenă - EMA (European Medicines Agency)

quintanrix

glaxosmithkline biologicals s.a. - davica toxoid, tetanus toxoid, inaktivirano bordetella oslovskemu kašlju, hepatitisu b površinski antigen (rdna), haemophilus influenzae tip b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; diphtheria - cepiva - quintanrix je indicirano za primarni imunizaciji dojenčkov (v prvem letu življenja) proti davici, tetanus, oslovski kašelj, hepatitis b in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b in za dvig imunizacije otrok med na drugo leto življenja. uporaba quintanrix je treba določiti na podlagi uradnih priporočil.

Respiporc FLUpan H1N1 Uniunea Europeană - slovenă - EMA (European Medicines Agency)

respiporc flupan h1n1

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - imunologi, inaktivirana virusna cepiva za prašiče, virus svinjske gripe - prašiči - aktivna imunizacija prašičev od starosti 8 tednov naprej proti virusu pandemičnega virusa hroščev virusa h1n1 za zmanjšanje virusne obremenitve pljuč in izločanja virusa. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

MenQuadfi Uniunea Europeană - slovenă - EMA (European Medicines Agency)

menquadfi

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokni - cepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Apexxnar Uniunea Europeană - slovenă - EMA (European Medicines Agency)

apexxnar

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pnevmokokne okužbe - cepiva - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. glej poglavja 4. 4 in 5. 1 za informacije o zaščiti proti specifičnim pnevmokoknim serotipom. apexxnar should be used in accordance with official recommendations. .

VidPrevtyn Beta Uniunea Europeană - slovenă - EMA (European Medicines Agency)

vidprevtyn beta

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - cepiva - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 in 5. 1 in product information document). uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Qdenga Uniunea Europeană - slovenă - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - cepiva - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.